Global Toxoplasmosis Treatment Market, By Type (Acute Toxoplasmosis, Central Nervous System (CNS) Toxoplasmosis, Congenital Toxoplasmosis, Ocular Toxoplasmosis, Others), Treatment (Diagnosis, Medication, Others), Population (Children, Adults), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Global toxoplasmosis treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.10% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
Moreover, technological advancement in treatment and diagnosis, rising prevalence of foodborne illnesses and rise in incidence of parasite infections globally also boost up the market growth. Continuous rising government awareness programmes and continuously increasing unhygienic environment in populated countries all over the world also boost up the market growth. Increasing new treatment options act as opportunity for the market growth. But, side effects related to the anti-allergic drugs, lack of awareness in developing countries and presence of alternative treatment may hamper the global toxoplasmosis treatment market.
Toxoplasmosis infection caused by the single-celled parasite known as Toxoplasma gondii. The infection usually occurs by eating undercooked contaminated meat, mother-to-child transmission during pregnancy and exposure from infected cat faeces. Toxoplasmosis infection may causes flu like symptoms in some people, although most of the infected population never shows any kind of symptoms. Other minor symptoms are headache, fever, fatigue, swollen lymph nodes, body aches and others. Moreover people who have weaken immune system such as HIV patients on chemotherapeutics may develop more-severe signs and symptoms of infection such as confusion, headache, poor coordination, lung problems that may resemble tuberculosis and others.
Toxoplasmosis parasite is the most common and found across the world. According to the Centre of Disease Control (CDC) more than 40 million men, women, and children in the U.S. carry the Toxoplasma parasite. In the U.S. it is estimated that 11% of population with the age of 6 and older have been infected with Toxoplasma.
Moreover according to the European Centre for Disease Prevention and Control (ECDC) in 2017, approximately 194 cases reported with Toxoplasmosis infection in 22 countries. France accounted highest cases with 79% share. The number of notifications per 100 000 living new-borns was 5.3 in the EU/EEA, with the highest rate in France (19.9), followed by Slovenia, Poland and Bulgaria.
This toxoplasmosis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Toxoplasmosis treatment Market Scope and Market Size
Toxoplasmosis treatment market is segmented on the basis of type, treatment, population, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the toxoplasmosis treatment market is segmented into acute toxoplasmosis, central nervous system (CNS) toxoplasmosis, congenital toxoplasmosis, ocular toxoplasmosis and others.
- On the basis of treatment, the toxoplasmosis treatment market is segmented into diagnosis, medication and others. Medication segment further divided into pyrimethamine/ clindamycin, sulfadiazine, folinic acid and others.
- On the basis of population, the toxoplasmosis treatment market is segmented into children and adults.
- On the basis of end-users, the toxoplasmosis treatment market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel Toxoplasmosis treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Toxoplasmosis treatment Market Country Level Analysis
Toxoplasmosis treatment market is analysed and market size information is provided by country, type, treatment, population, end-users and distribution channel as referenced above.
The countries covered in the toxoplasmosis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and increased clinical studies for the treatment. Asia-Pacific is expected to account for the largest market share over coming years for the Toxoplasmosis treatment market due to constant rise in the incidence of toxoplasmosis infection and rising demand for cost-efficient therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Toxoplasmosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Toxoplasmosis Treatment Market Share Analysis
Toxoplasmosis treatment market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to toxoplasmosis treatment market.
The major players covered in the toxoplasmosis treatment market are Pfizer Inc., Mylan N.V., Macleods Pharmaceuticals, Cadila Pharmaceuticals, Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Bayer AG, Sun Pharmaceutical Industries Ltd., Perrigo Pharmaceutical plc., Sandoz AG, Hikma Pharmaceutical PLC, Akron Inc., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.